Actylis and Novo Nordisk Pharmatech A/S have partnered to distribute pharmaceutical-grade Benzalkonium Chloride (BKC) in key European markets, including Germany, Spain, Portugal, the UK, and Ireland. This strategic collaboration leverages Novo Nordisk Pharmatech’s expertise in manufacturing high-standard quaternary ammonium compounds (Quats) with Actylis’s robust distribution network and industry knowledge. Aiming to serve the pharmaceutical and medical device sectors, this agreement is expected to enhance service quality and product availability.
Ian Jenning, SVP-President Europe at Actylis, sees this partnership as an extension of their existing North American collaboration, enriching Actylis Europe’s pharmaceutical product offerings and supporting the development of new applications for Novo Nordisk Pharmatech’s BKC. Samia Kappe, Chief Commercial Officer at Novo Nordisk Pharmatech, expressed excitement about reinforcing their collaboration with Actylis and anticipates a successful partnership in the European markets.
Actylis, a prominent manufacturer and global distributor, provides critical raw materials and ingredients for the life science industry. The company boasts a comprehensive infrastructure, including R&D facilities, manufacturing plants, warehousing hubs, and sales offices, aiming to deliver versatile solutions for pharmaceutical intermediates, regulatory starting materials, APIs, and excipients from clinical trials to commercial launches.
Novo Nordisk Pharmatech A/S specializes in producing high-quality Quats and Recombinant Insulin for pharmaceutical and biopharmaceutical applications. Their products adhere to the latest pharmacopeial standards, supported by CEPs, DMFs, and extensive regulatory documentation. The manufacturing site in Køge, Denmark, meets the rigorous quality standards set by the Danish Medicines Agency and the US FDA, underscoring both Actylis and Novo Nordisk Pharmatech’s commitment to quality and regulatory compliance.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.